

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 May 2025 (22.05.2025)



(10) International Publication Number
WO 2025/103501 A1

(51) International Patent Classification:

A61K 47/18 (2017.01) *A61K 39/395* (2006.01)
A61K 31/465 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/CN2024/132633

(22) International Filing Date:

18 November 2024 (18.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/132343

17 November 2023 (17.11.2023) CN

202411605853.8 11 November 2024 (11.11.2024) CN

(71) Applicant (for CN only): **WUXI BIOLOGICS (SHANGHAI) CO., LTD.** [CN/CN]; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN).

(71) Applicant (for all designated States except CN): **WUXI BIOLOGICS IRELAND LIMITED** [IE/IE]; Mullagharlin, Dundalk, Co Louth, A91 X56F (IE).

(72) Inventors: **CHEN, Qizhou**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **LEI, Bin**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **WANG, Chenxi**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **WANG, Tingting**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **ZHOU, Fangyuan**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **GUO, Jeremy**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **JIN, Zhaowei**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **CHEN, Quanmin**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN).

(74) Agent: **CCPIT PATENT AND TRADEMARK LAW OFFICE**; 10/F, Ocean Plaza, 158 Fuxingmennei Street, Xicheng District, Beijing 100031 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: VISCOSITY-REDUCING AND STABILIZING LIQUID FORMULATIONS FOR HIGH CONCENTRATION PROTEIN FORMULATIONS

(57) Abstract: A series of viscosity-reducing and stabilizing formulations for high concentration protein formulations, which are meticulously tailored to significantly decrease the viscosity and increase the stability of high concentration biopharmaceuticals. The viscosity-reducing and stabilizing formulations can be used in high concentration biopharmaceutical products and can bring considerable potential for enhancing the stability during preparation and storage and elevating the feasibility of high concentration biopharmaceutical products.

WO 2025/103501 A1